
Record of Telephone Conversation, December 14, 2012 - Flublok


 

Submission Type: BLA    Submission ID: 125285/0    Office: OVRR

Product:

Influenza Vaccine

Applicant:

Protein Sciences Corporation

Telecon Date/Time: 14-Dec-2012 03:35 PM        Initiated by FDA? Yes

Telephone Number: Communicated via e-mail

Communication Categorie(s):

1. Advice

2. Information Request

Author: TIMOTHY FRITZ

Telecon Summary:

RT investigation summary, Flublok shelf life

FDA Participants: Timothy Fritz

Non-FDA Participants: Penny Post

Trans-BLA Group: No

Related STNs: None

Related PMCs: None

Telecon Body:

From:                    Fritz, Timothy

Sent:                      Friday, December 14, 2012 3:35 PM

To:                         'Penny Post'

Subject:                 CBER advice/information request for STN 125285 (Flublok)

 

Importance:           High

 

Attachments:         CBER advice information request STN 125285.pdf

Dear Dr. Post-

 

Our review of Protein Sciences Corporation's Flublok Biologics License Application (STN 125285) is ongoing. We have the following advice and request for additional information:

 

1.     CBER does not agree to an extension of the Flublok shelf life.  When available, CBER recommends submission of data that provides a statistically valid assessment of stability, as described in Krause, 2009 (Biologicals 37: 369-378), with data from product manufactured over several seasons to support extension of shelf life.

a.      PSC should provide a statistical analysis to support the number of product lots used, and a scientific rationale for the number of seasons examined.

b.     In the model presented for determining shelf life, the lowest release limit (LRL) of –b(4)----- should be used at the onset of the dating period, and the Lower Limit (LL) of –b(4)-------- can be used to determine shelf life when assay and regression slope precision are taken into consideration.  Assay variability must be considered as a factor in your calculation of shelf life.

c.      When submitting stability data, the number of vials tested to generate the potency value and the % RSD acceptance criterion should be noted.

d.     In previous submissions, you described the biphasic nature of monovalent bulk decay. Since this could contribute to the differences in H3 and B decay slopes for product lots –b(4)---------------------------------, please consider this when planning your future studies to extend product shelf life.

 

2.     We acknowledge your July 16, 2012, submission (Amendment 57) in which a summary of your –b(4)---------------------------------- investigations to that date was provided. Please provide an updated, complete summary of all of PSC's investigations of the –b(4)--------, the results obtained, the conclusions reached, and a discussion of why PSC believes the –b(4)-------- does not pose any risk.

 

Please provide your response as an amendment to STN 125285 as soon as possible. If you have any questions, please contact the Regulatory Project Chair, Dr. Timothy Fritz, at 301-796-2640.

 

Thank you.

Timothy A. Fritz, Ph.D. 
Microbiologist 
FDA/CBER/OVRR/DVRPA/CMC2 
WOC2 HFM-478
1451 Rockville Pike 
Rockville, MD 20852 
Phone: 301-796-2640 
Fax: 301-827-1597

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.

 